These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11918070)

  • 1. Enhancement of fibrinolytic activity of U937 cells by malformin A1.
    Koizumi Y; Hasumi K
    J Antibiot (Tokyo); 2002 Jan; 55(1):78-82. PubMed ID: 11918070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolytic activation promoted by the cyclopentapeptide malformin: involvement of cytoskeletal reorganization.
    Koizumi Y; Fukudome H; Hasumi K
    Biol Pharm Bull; 2011; 34(9):1426-31. PubMed ID: 21881228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of RSK1 activation in malformin-enhanced cellular fibrinolytic activity.
    Koizumi Y; Nagai K; Gao L; Koyota S; Yamaguchi T; Natsui M; Imai Y; Hasumi K; Sugiyama T; Kuba K
    Sci Rep; 2018 Apr; 8(1):5472. PubMed ID: 29615689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship of cyclic pentapeptide malformins as fibrinolysis enhancers.
    Koizumi Y; Nagai K; Hasumi K; Kuba K; Sugiyama T
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5267-5271. PubMed ID: 27680590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of fibrinolysis by plactins: structure-activity relationship and effects in human U937 cells and in mice.
    Inoue T; Hasumi K; Sugimoto M; Endo A
    Thromb Haemost; 1998 Mar; 79(3):591-6. PubMed ID: 9531047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of plasminogen activation by surfactin C: augmentation of fibrinolysis in vitro and in vivo.
    Kikuchi T; Hasumi K
    Biochim Biophys Acta; 2002 Apr; 1596(2):234-45. PubMed ID: 12007605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fungal malformins inhibit bleomycin-induced G2 checkpoint in Jurkat cells.
    Hagimori K; Fukuda T; Hasegawa Y; Omura S; Tomoda H
    Biol Pharm Bull; 2007 Aug; 30(8):1379-83. PubMed ID: 17666789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of plasminogen binding to U937 cells and fibrin by complestatin.
    Tachikawa K; Hasumi K; Endo A
    Thromb Haemost; 1997 Jan; 77(1):137-42. PubMed ID: 9031464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-Scale CRISPR/Cas9 Screening Reveals Squalene Epoxidase as a Susceptibility Factor for Cytotoxicity of Malformin A1.
    Koizumi Y; Fukushima J; Kobayashi Y; Kadowaki A; Natsui M; Yamaguchi T; Imai Y; Sugiyama T; Kuba K
    Chembiochem; 2019 Jun; 20(12):1563-1568. PubMed ID: 30734978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol-induced up-regulation of fibrinolytic activity and plasminogen activators in human monocytes.
    Tabengwa EM; Wheeler CG; Yancey DA; Grenett HE; Booyse FM
    Alcohol Clin Exp Res; 2002 Aug; 26(8):1121-7. PubMed ID: 12198385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.
    Aoki N; Moroi M; Tachiya K
    Thromb Haemost; 1978 Feb; 39(1):22-31. PubMed ID: 77050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
    Urano S; Metzger AR; Castellino FJ
    Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2568-71. PubMed ID: 2523073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis.
    Thorsen S; Astrup T
    Thromb Diath Haemorrh; 1974 Dec; 32(2-3):306-24. PubMed ID: 4281113
    [No Abstract]   [Full Text] [Related]  

  • 20. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR; De Wreede K; Demarsin E; Collen D
    Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.